Risk Assessment Standards From OMB Are Too Broad, FDA’s Galson Says
Executive Summary
FDA is concerned that the White House Office of Management & Budget's definition of "risk assessment" outlined in its Proposed Risk Assessment Bulletin would constrain agency action by requiring too many analyses